Sage Therapeutics Stock Rockets on Two Positive Phase III Trials in Postpartum Depression Post author:Sam Post published:November 8, 2017 Post category:BioPharma The positive results support the company’s planned regulatory submissions. Source: BioSpace You Might Also Like argenx Bags $231M in Upsized U.S. IPO December 13, 2017 Groundbreaking: Amicus Surges as the FDA Changes Its Tune on Fabry Disease Drug July 10, 2017 Investors Breathe a Sigh of Relief Cempra's Skin Infection Drug Hits Phase III Goals February 23, 2017
Investors Breathe a Sigh of Relief Cempra's Skin Infection Drug Hits Phase III Goals February 23, 2017
